NASDAQ · KRRO
Healthcare · Biotechnology
$13.28
Down-$0.01 (-0.08%)
Updated Aug 15, 2026, 12:21 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
KRRO closed at $13.28 after 21 trading sessions, up 8.41% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $13.34 | $13.34 | $12.72 | $13.28 | 47.07K |
| Aug 13, 2026 | $13.39 | $13.93 | $12.89 | $13.29 | 113.83K |
| Aug 12, 2026 | $13.44 | $13.58 | $12.79 | $13.35 | 95.41K |
| Aug 11, 2026 | $13.61 | $14.00 | $13.275 | $13.32 | 109.84K |
| Aug 10, 2026 | $13.24 | $13.73 | $13.00 | $13.49 | 78.59K |
| Aug 7, 2026 | $12.24 | $13.30 | $12.24 | $13.25 | 120.2K |
| Aug 6, 2026 | $11.50 | $12.24 | $11.38 | $12.12 | 173.15K |
| Aug 5, 2026 | $11.46 | $11.695 | $11.19 | $11.50 | 105.84K |
| Aug 4, 2026 | $10.93 | $11.41 | $10.5268 | $11.35 | 132.45K |
| Aug 3, 2026 | $10.46 | $10.88 | $10.22 | $10.74 | 94.7K |
| Jul 31, 2026 | $10.53 | $10.53 | $9.76 | $10.37 | 115.21K |
| Jul 30, 2026 | $10.26 | $10.5914 | $10.00 | $10.45 | 129.7K |
| Jul 29, 2026 | $10.53 | $10.565 | $9.92 | $10.07 | 132.34K |
| Jul 28, 2026 | $10.80 | $10.93 | $10.20 | $10.50 | 153.99K |
| Jul 27, 2026 | $10.93 | $11.25 | $10.25 | $10.72 | 131.2K |
| Jul 24, 2026 | $11.60 | $11.60 | $10.605 | $10.64 | 146.97K |
| Jul 23, 2026 | $11.47 | $11.58 | $11.03 | $11.53 | 138.16K |
| Jul 22, 2026 | $11.89 | $12.07 | $11.54 | $11.70 | 133.39K |
| Jul 21, 2026 | $12.04 | $12.09 | $11.62 | $11.96 | 233.73K |
| Jul 20, 2026 | $12.31 | $12.70 | $11.29 | $11.50 | 232.43K |
| Jul 17, 2026 | $11.86 | $12.36 | $11.50 | $12.25 | 169.77K |
The latest Smart Investors Daily articles mentioning KRRO.
KRRO research
Company profile and research snapshot.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2026 | HC Wainwright & Co. | Buy | — |
| May 18, 2026 | Citigroup | Buy | — |
| Mar 13, 2026 | Cantor Fitzgerald | Overweight | — |
| Mar 13, 2026 | Raymond James | Outperform | — |
| Feb 19, 2026 | Clear Street | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 6, 2026
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.31) by 18.32 percent. This is a 60.95 percent increase over losses of $(2.74) per share from the
Yahoo · Jul 10, 2026
CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to seven newly hired employees. Korro granted four new employees nonstatutory stock options to purchase 6,000 shares, in the aggregate, of Korro’s common stock at
Yahoo · Jul 8, 2026
Korro Bio, Inc. (KRRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Benzinga · May 19, 2026
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungsDemonstrated >90% editing of SERPINA1 transcript
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KRRO.
